Has Floyd Fortuin, MD received payments from drug or device companies?

Yes. Drug and device makers reported $15,300 in general payments to Floyd Fortuin, MD across 71 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Floyd Fortuin, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Floyd Fortuin, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Floyd Fortuin, MD

Interventional Cardiology · Phoenix, AZNPI 1861475436

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (58.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by AstraZeneca at 58.8% of the total. Reporting peaked in 2019 at $5,699 and has fallen 66.5% since, to $1,912 in 2025.

$15,300in general payments, 2019–2025

Across 71 payments — averaging $215.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$9K
Edwards Lifesciences$2K
Abbott$2K
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$893
Medtronic$490
Boston Scientific$299
plus $613 from 7 others

$247,940in research payments, 2019–2025

Across 73 payments — averaging $3396.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

CSL Behring$142K
W. L. Gore & Associates, Inc.$55K
Procyrion, Inc.$34K
Neovasc Medical Inc$15K
Shockwave Medical, Inc$1K

What the payments were for

Consulting fees$9,00059%
Travel & lodging$2,15814%
Food & beverage$4,06627%
Education$760%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	9	$9,000
Edwards Lifesciences	20	$2,381
Abbott	13	$1,623
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	10	$893
Medtronic(2 entities)	9	$490
Boston Scientific	2	$299
Novartis	2	$262
Johnson & Johnson	1	$123
W. L. Gore & Associates, Inc.	1	$120
ZOLL Circulation Inc	1	$48
E.r. Squibb & Sons, L.L.C.	1	$28
Cardiva Medical, Inc.	1	$18
Philips North America LLC	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

EPANOVA$9,000
EVOQUE$937
Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$528
TENDYNE$464
LifeVest$361
SAPIEN 3 Ultra RESILIA$298
LEQVIO$262
PASCAL$175
WATCHMAN Access System$174
Edwards SAPIEN 3 Transcatheter Heart Valve$167
PORTICO$161
FATHOM$125
XARELTO$123
GORE CARDIOFORM Septal Occluder$120
COREVALVE EVOLUT R$118

How this compares

$15,300 in reported general payments places this provider in the 60th percentile of 223 interventional cardiology providers in Arizona.

See all interventional cardiology providers in Arizona →

Medicare billing

Part B allowed, 2024

$152,855

Medicare patients

787

Services billed

1,236

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	28	$45,694
WegovySemaglutide	11	$14,237
Atorvastatin Calcium	65	$823
Metoprolol Succinate	24	$734
Ezetimibe	27	$558
Rosuvastatin Calcium	41	$524
ClopidogrelClopidogrel Bisulfate	30	$414
Losartan Potassium	28	$399
Warfarin Sodium	27	$381
Carvedilol	12	$263
Amlodipine Besylate	37	$176
Hydrochlorothiazide	15	$103
Tamsulosin Hcl	13	$101
Lisinopril	19	$59

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Phoenix

Paul SorajjaPhoenix$1.1M
Timothy ByrnePhoenix$614K
Haidar YassinPhoenix$434K
Akil LoliPhoenix$160K
Nishant GuptaPhoenix$145K
Richard HeuserPhoenix$68K
Nezar FallujiPhoenix$50K
Ahmad JabriPhoenix$39K
Edward EvansPhoenix$36K
Basil Al KhatibPhoenix$33K

See the full list for Arizona →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →